• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Neogen Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    10/27/25 9:08:33 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NEOG alert in real time by email
    8-K
    false000071137700007113772025-10-232025-10-23

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): October 23, 2025

     

     

    Neogen Corporation

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Michigan

    0-17988

    38-2367843

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    620 Lesher Place

     

    Lansing, Michigan

     

    48912

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (517) 372-9200

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.16 par value per share

     

    NEOG

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On October 23, 2025, the Company held its 2025 Annual Meeting of Shareholders. At the meeting, 195,086,461 of the 217,298,626 shares outstanding and entitled to vote were present and voted. The matters listed below were submitted to a vote of the shareholders though the solicitation of proxies. The proposals are described in detail in the Company’s Proxy Statement dated as of, and filed with Securities and Exchange Commission on, September 12, 2025. The voting results are as follows:

     

    Proposal 1 – Election of Directors

     

    Nominee

    For

    Withheld

    Thierry L. Bernard

     

     

    168,950,135

     

     

     

    16,330,540

    Mikhael Nassif

     

     

    171,847,536

     

     

     

    13,433,139

    Avi Pelossof

     

     

    171,839,634

     

     

     

    13,441,041

    Andrea F. Wainer

     

     

    169,573,203

     

     

     

    15,707,472

     

     

     

    Proposal 2 – To Approve, by Non-Binding Vote, the Compensation of the Company’s Named Executive Officers

    The shareholders did not approve, by non-binding vote, the compensation of the Company’s named executive officers, as disclosed in the proxy materials.

    For

    Against

    Abstain

    Broker Non-Vote

    167,126,873

     

     

     

    17,679,601

     

     

     

    412,667

     

     

     

    9,805,786

     

    Proposal 3 – Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm

    The shareholders ratified the appointment of BDO USA, P.C. as the Company’s auditors for the fiscal year ending May 31, 2026.

    For

    Against

    Abstain

    Broker Non-Vote

    181,630,320

     

     

     

    13,148,285

     

     

     

    307,856

    -


    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit

    Description

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document).


     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    NEOGEN CORPORATION

     

     

     

     

    Date:

    October 27, 2025

    By:

    /s/ Amy M. Rocklin

     

     

     

    Name: Amy M. Rocklin
    Title: Chief Legal & Compliance Officer, Corporate Secretary

     


    Get the next $NEOG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEOG

    DatePrice TargetRatingAnalyst
    7/29/2025Outperform → Mkt Perform
    William Blair
    12/19/2024$15.00Buy
    Guggenheim
    6/16/2023$22.00Overweight
    Wells Fargo
    11/22/2022Mkt Perform → Outperform
    William Blair
    7/12/2022$25.00Neutral
    Piper Sandler
    More analyst ratings

    $NEOG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neogen® Corporation Announces Appointment of Bryan Riggsbee as Chief Financial Officer

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Bryan Riggsbee as its new Chief Financial Officer effective November 3, 2025. Riggsbee will oversee Neogen's global finance organization and join the company's Executive Leadership Team, reporting directly to Chief Executive Officer Mike Nassif. To ensure a smooth transition, David Naemura is expected to remain with the Company until the end of the calendar year. Riggsbee brings over 25 years of financial leadership experience across the diagnostics and healthcare industries. He joins Neogen from bioMérieux where he served as Chief Financial Officer of its $2 billion Nort

    10/30/25 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces First-Quarter 2026 Results

    Revenue of $209.2 million Net Income of $36.3 million; Adjusted Net Income1 of $9.4 million Adjusted EBITDA1 of $35.5 million Completed divestiture of Cleaners & Disinfectants business, repaid $100.0 million of debt Welcomed Mike Nassif as Chief Executive Officer and President, effective August 11 Restructuring actions taken at the end of September to right-size the cost base Reaffirming full-year outlook 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the first quarter ended August 31, 2025. "I see tremendous opportunity ahead to leverage Neogen's strong, longstanding l

    10/9/25 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Renews Official Sponsorship with US Equestrian to Continue Advancing Equine Health Education

    Neogen® Corporation (NASDAQ: NEOG) announced today that it has renewed its commitment to the United States Equestrian Federation, extending the relationship first launched last year. Since joining US Equestrian in April 2024, Neogen has provided valuable support, resources, and educational tools to benefit the Federation and its members. As part of the renewed collaboration, Neogen and US Equestrian will once again develop member-accessible educational materials on prevention and treatment protocols for equine botulism—one of the most dangerous neuromuscular conditions in horses. This deadly neurotoxin, often referred to as a silent killer, can be found in hay, feed, and soil, posing a de

    9/25/25 5:26:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Nassif Mikheal bought $1,106 worth of shares (177 units at $6.25) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    11/7/25 12:20:20 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Gupta Aashima bought $99,987 worth of shares (16,000 units at $6.25), increasing direct ownership by 270% to 21,917 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    5/12/25 2:30:47 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Woteki Catherine E bought $29,831 worth of shares (5,770 units at $5.17), increasing direct ownership by 77% to 13,244 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/25/25 4:32:35 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Nassif Mikheal bought $1,106 worth of shares (177 units at $6.25) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    11/7/25 12:20:20 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: New insider Nassif Mikheal claimed ownership of 620 shares (SEC Form 3)

    3/A - NEOGEN CORP (0000711377) (Issuer)

    11/7/25 12:12:52 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CFO Riggsbee Richard Bryan was granted 178,855 shares (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    11/5/25 9:20:36 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neogen downgraded by William Blair

    William Blair downgraded Neogen from Outperform to Mkt Perform

    7/29/25 3:32:27 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Guggenheim initiated coverage on Neogen with a new price target

    Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00

    12/19/24 8:18:19 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Wells Fargo initiated coverage on Neogen with a new price target

    Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00

    6/16/23 7:34:39 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    SEC Filings

    View All

    Neogen Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    10/30/25 8:47:15 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: Neogen Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - NEOGEN CORP (0000711377) (Filer)

    10/28/25 11:28:39 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: Neogen Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K/A - NEOGEN CORP (0000711377) (Filer)

    10/27/25 10:55:23 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Leadership Updates

    Live Leadership Updates

    View All

    Neogen® Corporation Announces Appointment of Bryan Riggsbee as Chief Financial Officer

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Bryan Riggsbee as its new Chief Financial Officer effective November 3, 2025. Riggsbee will oversee Neogen's global finance organization and join the company's Executive Leadership Team, reporting directly to Chief Executive Officer Mike Nassif. To ensure a smooth transition, David Naemura is expected to remain with the Company until the end of the calendar year. Riggsbee brings over 25 years of financial leadership experience across the diagnostics and healthcare industries. He joins Neogen from bioMérieux where he served as Chief Financial Officer of its $2 billion Nort

    10/30/25 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Board Transition with Appointment of Avi Pelossof and the Retirement of William Boehm

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that William Boehm has chosen to retire from the Company's Board of Directors, effective October 23, 2025. Mr. Boehm has served on Neogen's Board since 2011 and currently serves on the Compensation & Talent Management Committee and chairs the Audit Committee. "On behalf of the entire Board and leadership team, I want to express our deep gratitude to Bill for his many years of dedicated service to Neogen," said James C. Borel, Chair of the Neogen Board of Directors. "Bill's insight, guidance, and commitment to our mission have been invaluable in shaping Neogen's path forward. His contributions

    8/14/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Corporation Announces Appointment of Mike Nassif as CEO and President

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Mike Nassif as its new Chief Executive Officer and President, effective August 11, 2025. He also will join Neogen's Board of Directors at that time. Mr. Nassif succeeds John Adent who will, as previously announced, step down after an eight-year career at the company. Mr. Nassif brings a wealth of experience and a proven track record of success in the healthcare and diagnostics industry. Mr. Nassif joins Neogen from Siemens Healthineers, where he was Global President of the Point-of-Care Diagnostics business and instrumental in driving significant growth. "I am very exci

    7/24/25 9:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Financials

    Live finance-specific insights

    View All

    Neogen Announces First-Quarter 2026 Results

    Revenue of $209.2 million Net Income of $36.3 million; Adjusted Net Income1 of $9.4 million Adjusted EBITDA1 of $35.5 million Completed divestiture of Cleaners & Disinfectants business, repaid $100.0 million of debt Welcomed Mike Nassif as Chief Executive Officer and President, effective August 11 Restructuring actions taken at the end of September to right-size the cost base Reaffirming full-year outlook 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the first quarter ended August 31, 2025. "I see tremendous opportunity ahead to leverage Neogen's strong, longstanding l

    10/9/25 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces First-Quarter Earnings Release Date

    Neogen® Corporation (NASDAQ:NEOG) will issue its first-quarter earnings release before the opening of the market on October 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing: Toll-Free - North America: 1-800-549-8228 International: (+1) 646-564-2877 Conference ID: 49915 The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "Events & Presentations" subheading. A replay of the conference call and webcast will be available shortly following the conclusion of the

    9/18/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Fourth-Quarter 2025 Results

    Revenue of $225.5 million. Net loss of $612.2 million due to non-cash goodwill impairment; $(2.82) per diluted share. Adjusted Net Income1 of $11.3 million; $0.05 per diluted share. Adjusted EBITDA1 of $40.6 million. 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the fourth quarter ended May 31, 2025. "The softer end-market conditions continued in the fourth quarter, with elevated trade uncertainty and the cumulative effect of the last four years of inflation on food production," said John Adent, Neogen's President and Chief Executive Officer. "We believe the Food Safety end mar

    7/29/25 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 4:28:12 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 11:16:20 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    2/13/24 5:09:41 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care